Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes (Q33270804)

24 July 2017

1 reference

title

Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes (English)

1 reference

24 July 2017

6

Francesca Arruga

1 reference

24 July 2017

Giuseppe Saglio

11

0 references

author name string

Daniela Cilloni

1

1 reference

24 July 2017

Emanuela Messa

2

1 reference

24 July 2017

Francesca Messa

3

1 reference

24 July 2017

Sonia Carturan

4

1 reference

24 July 2017

Ilaria Defilippi

5

1 reference

24 July 2017

Valentina Rosso

7

1 reference

24 July 2017

Renata Catalano

8

1 reference

24 July 2017

Enrico Bracco

9

1 reference

24 July 2017

Paolo Nicoli

10

1 reference

24 July 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

Annals of the New York Academy of Sciences

24 July 2017

published in

1 reference

24 July 2017

volume

1089

1 reference

24 July 2017

page(s)

411-423

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.030

24 July 2017

1 reference

RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.030

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.030

Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.030

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.030

The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.030

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.030

Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.030

STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.030

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.030

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.030

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.030

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.030

DNA methylation in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.030

Methylation profiling in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.030

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.030

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.030

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.030

Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.030

Relationships between chromatin organization and DNA methylation in determining gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.030

Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.030

The EVI-1 gene--its role in pathogenesis of human leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.030

The EVI1 gene in myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.030

Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.030

Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.030

Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.030

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.030

21 January 2018

Identifiers

DOI

10.1196/ANNALS.1386.030

1 reference

24 July 2017

1 reference